Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.55 |
| ▸ | FGFR4 | P22455 | 10/20 | 0.54 |
| ▸ | KDR | P35968 | 10/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23328286 | 0.86 | FGFR1 (0.60) | FGFR1FGFR4KDR | |
| SCHEMBL23328285 | 0.84 | FGFR1 (0.59) | FGFR1FGFR4KDR | |
| SCHEMBL21783930 | 0.82 | FGFR1 (0.57) | FGFR1FGFR4KDR | |
| SCHEMBL23328287 | 0.80 | FGFR1 (0.55) | FGFR1FGFR4KDR | |
| SCHEMBL30058260 | 0.76 | FGFR1 (0.62) | FGFR1FGFR4KDR | |
| SCHEMBL23297465 | 0.76 | FGFR1 (0.62) | FGFR1FGFR4KDR | |
| SCHEMBL29735728 | 0.75 | FGFR1 (0.69) | FGFR1FGFR4KDR | |
| SCHEMBL23297424 | 0.75 | FGFR1 (0.69) | FGFR1FGFR4KDR | |
| SCHEMBL23328312 | 0.75 | FGFR1 (0.60) | FGFR1FGFR4KDR | |
| SCHEMBL23297388 | 0.73 | FGFR1 (0.62) | FGFR1FGFR4KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210340142-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | BETTA PHARMACEUTICALS CO., LTD (CN) | 2021-11-04 | — | — | US | disclosed |
| EP-3845534-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | Betta Pharmaceuticals Co., Ltd (CN) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020043078-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | 贝达药业股份有限公司 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210340142-A1 | SALT FORM AND CRYSTAL FORM OF NOVEL AZATRICYCLIC COMPOUND AND USE THEREOF | CS, MDH2, MDH1 | FGFR1 471/4885FGFR4 787/4885KDR 4182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.